ArticleJournal of Cancer2020

Development and validation of a robust multigene signature as an aid to predict early relapse in stage I-III clear cell and papillary renal cell cancer.

Da-Long Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.